骨质疏松疾病负担与治疗现状  

The Disease Burden and Treatment Situation of Osteoporosis

作　　者：吴晶[1] 刘新灵[1] 贺小宁[1] 丁丽曼[1] 

机构地区：[1]天津大学药物科学与技术学院,天津300072

出　　处：《中国医疗保险》2015年第11期57-60,共4页China Health Insurance

摘　　要：目的:本文旨在总结骨质疏松症患者的流行病学特征、疾病负担和国内外诊断治疗现状,为医疗卫生决策者、医务工作者和患者充分认识骨质疏松症的临床和卫生经济现状提供参考。方法 :利用数据库检索骨质疏松症相关研究的中、英文文献和相关诊疗指南,对文献信息进行汇总综述。结果与结论 :骨质疏松症由于早期缺乏明显症状,诊断和治疗率不足20%,国内外研究综合显示骨质疏松骨折患者中仅有20%-30%接受了骨折诊断治疗。骨质疏松症的治疗成本较高,给患者和医疗保健系统带来了沉重的经济负担。目前阿仑膦酸钠、利塞膦酸钠和特立帕肽是治疗骨质疏松症的一线用药。应做好对骨质疏松症的早期诊断和药物干预治疗。Objective： To summarize the epidemiological features, disease burden, diagnosis, and treatment situation of osteoporosis in the world, and provide reference for health care policy makers, clinical workers, and patients to understand the clinical and health-economical status of osteoporosis. Methods： Literatures and Guidelines about osteoporosis written in English and Chinese were searched and summarized. Results and Conclusions： Due to lack of obvious symptoms in early stage, the diagnosis and treatment rate of osteoporosis was less than 20%. Domestically and internationally published studies showed that the proportion of diagnosis and treatment among patients with fracture is only 20%-30%. The total cost of osteoporosis is high, which brings heavy economic burden to patients and the health care system. Alendronate, Risedronate and Teriparatide have been used as the first-line therapy agents. Early diagnosis and medical interventions are important to control osteoporosis.

关 键 词：骨质疏松 骨折 疾病负担 诊断治疗 

分 类 号：R580[医药卫生—内分泌]